Short answer
Amgen (AMGN) filed its Q3 2026 10-Q quarterly report on Nov 4, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $10.4B (up 8.5% year over year) with net income of $3.9B.
Q3 2026 key financials · XBRL
- Revenue
- $10.4B
- +8.5% YoY · +3.1% QoQ
- Net income
- $3.9B
- +20.1% YoY · +62.7% QoQ
- Operating margin
- 35.8%
- EPS (diluted)
- $7.08
- +19.4% YoY · +62.0% QoQ
Source: XBRL data from the Amgen (AMGN) Q3 2026 10-Q on SEC EDGAR. USD.
Amgen Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $10,365M, up 8% YoY from $9,557M, driven by product-sales volume growth
- Operating margin 35.8% vs 26.4% YoY, with operating income $3,710M vs $2,526M
- Best product: Repatha $1,085M, worst: Prolia $1,139M, down 45% YoY amid biosimilar competition
- Cash $13,190M vs $9,129M at December 31, 2025, with nine-month operating cash flow $10,432M vs $8,355M
- Outlook: volume growth offset by net-price declines, with continued Prolia and XGEVA erosion from biosimilars
Risk Factors
- TAVNEOS withdrawal risk: FDA proposed revoking U.S. approval after liver-injury concerns and questioned ADVOCATE data reliability
- TAVNEOS international risk: European Commission revoked authorization in August 2026, with other regulators restricting or reviewing use
- Medicare pricing pressure: CMS pricing reduced ENBREL profitability from January 1, 2026, with Otezla pricing beginning January 2027
- State reimbursement risk: Colorado established an ENBREL upper payment limit effective no earlier than January 1, 2027
- Regulatory capacity risk: FDA staffing and budget reductions could delay application reviews and approvals
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Amgen quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.